Anthony G. Quinn Acquires 4,100 Shares of Aeglea Bio Therapeutics Inc (AGLE) Stock

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Director Anthony G. Quinn acquired 4,100 shares of Aeglea Bio Therapeutics stock in a transaction dated Friday, December 1st. The stock was purchased at an average cost of $4.53 per share, with a total value of $18,573.00. Following the completion of the purchase, the director now owns 14,100 shares of the company’s stock, valued at $63,873. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Aeglea Bio Therapeutics Inc (AGLE) traded up $0.03 during trading hours on Thursday, hitting $4.91. 62,815 shares of the company were exchanged, compared to its average volume of 65,900. Aeglea Bio Therapeutics Inc has a 12-month low of $2.81 and a 12-month high of $8.14.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. The firm had revenue of $1.26 million during the quarter. analysts expect that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current year.

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in shares of Aeglea Bio Therapeutics during the first quarter worth $157,000. Renaissance Technologies LLC bought a new position in shares of Aeglea Bio Therapeutics during the first quarter worth $270,000. Vanguard Group Inc. boosted its position in shares of Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after acquiring an additional 12,966 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of Aeglea Bio Therapeutics during the second quarter worth $653,000. Hedge funds and other institutional investors own 46.89% of the company’s stock.

Separately, Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Friday, November 10th.

ILLEGAL ACTIVITY WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3080607/anthony-g-quinn-acquires-4100-shares-of-aeglea-bio-therapeutics-inc-agle-stock.html.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.